超声引导的射频消融（RFA）已经应用于拒绝手术或积极观察的乳头状甲状腺癌（PTC）患者中。然而，长期结果仍然有限。该研究旨在评估使用RFA治疗T1N0M0孤立型PTC患者的临床结果，覆盖了超过5年的随访时间。本回顾性研究包括358名使用RFA治疗的孤立T1N0M0 PTC患者，并进行了至少5年的随访。双极RFA程序采用液体分离技术、喉间隙入路和移动射击技术进行。主要结果包括疾病进展，包括淋巴结转移（LNM）、复发性肿瘤、持续性肿瘤和远处转移。次要结果包括体积缩小率、完全消失率、并发症和延迟手术。在平均随访期75.5±9.7个月中，总体疾病进展为5.0%。LNM、复发性肿瘤和持续性肿瘤的发生率分别为1.4%、3.1%和0.6%。T1a和T1b组的疾病进展（5.0% vs. 5.5%，p=1.000）、LNM（1.3% vs. 1.8%，p=.568）、复发性肿瘤（3.3% vs. 1.8%，p=.872）、持续性肿瘤（0.3% vs. 1.8%，p=.284）和5年无复发生存率（95.4% vs. 96.4%，p=.785）没有显著差异。体积缩小率为100.0±0.3%，有96.9%的肿瘤消失。没有并发症发生。没有因为焦虑而接受延迟手术的患者。RFA是一种有效且安全的选择，可为拒绝手术或积极观察的T1N0M0 PTC患者提供微创治疗方式。在平均随访期75.5±9.7个月中，总体乳头状甲状腺癌疾病进展为5.0％。 体积缩小率为100.0±0.3％，有96.9％的肿瘤消失。T1a和T1b组的疾病进展和5年无复发生存率相似。没有患者出现并发症或因焦虑而接受延迟手术。©2023年美国癌症协会。

Ultrasound-guided radiofrequency ablation (RFA) has been used in patients with papillary thyroid carcinoma (PTC) who refuse surgery or active surveillance. However, the long-term outcomes are still limited. This study aimed to evaluate the clinical outcomes of RFA for solitary T1N0M0 PTC in a large cohort over a more than 5-year follow-up period.This retrospective study included 358 patients with solitary T1N0M0 PTC who were treated with RFA and followed for at least 5 years. The bipolar RFA procedure was performed using hydrodissection technique, transisthmic approach, and moving-shot technique. The primary outcomes were disease progression, including lymph node metastasis (LNM), recurrent tumor, persistent tumor, and distant metastasis. The secondary outcomes were volume reduction rate, complete disappearance rate, complications, and delayed surgery.During a mean follow-up period of 75.5 ± 9.7 months, the overall disease progression was 5.0%. The incidence of LNM, recurrent tumor, and persistent tumor was 1.4%, 3.1%, and 0.6%, respectively. There were no significant differences in the disease progression (5.0% vs. 5.5%, p = 1.000), LNM (1.3% vs. 1.8%, p = .568), recurrent tumor (3.3% vs. 1.8%, p = .872), persistent tumors (0.3% vs. 1.8%, p = .284), and 5-year recurrence-free survival rates (95.4% vs. 96.4%, p = .785) in the T1a and T1b groups. Volume reduction rate was 100.0 ± 0.3%, with 96.9% of tumors disappearing. No complications occurred. No patients underwent delayed surgery because of anxiety.RFA is an effective and safe alternative for patients with T1N0M0 PTC and can offer a minimally invasive curative option for patients who refuse surgery or active surveillance.During a mean follow-up period of 75.5 ± 9.7 months, the overall papillary thyroid carcinoma disease progression was 5.0%. The volume reduction rate was 100.0 ± 0.3%, with 96.9% of tumors disappearing. The T1a and T1b groups had similar incidence of disease progression and 5-year recurrence-free survival rates. No patients experienced complications or underwent delayed surgery because of anxiety.© 2023 American Cancer Society.